Small Molecules
26 February 2015
Parkinson’s disease (PD): EU Commission approves Xadago® (safinamide) for mid-late stage PD patients26 February 2015
Bristol-Myers Squibb’s clinical candidate represents a new class of drugs potentially able to address unmet medical needs in HIV-1 patients26 February 2015
ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour26 February 2015
Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain26 February 2015
Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys25 February 2015
Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma25 February 2015
48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation24 February 2015
Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma23 February 2015
Taiho Oncology, Inc. Announces TAS-102 New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA23 February 2015
Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study23 February 2015
Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib23 February 2015
Savara Pharmaceuticals’ AeroVanc Meets Primary Endpoint of MRSA Reduction in Phase 2 Trial in People with Cystic Fibrosis20 February 2015
FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)20 February 2015
Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study of OCR-00220 February 2015
ReveraGen BioPharma Announces Start Of Phase 1 Clinical Trial Of VBP15 Dissociative Steroid Drug20 February 2015
Lilly Provides Update on Evacetrapib Phase 3 Trial20 February 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced MelanomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports